Radiopharm trial advances to higher dose in HER2+ cancer study
Tweet Send to a Friend
Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced that its Data Safety and Monitoring Committee (DSMC) has recommended advancing its 177Lu-RAD202 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


